Skip to content
10-Q

Quarterly Report

PASITHEA THERAPEUTICS CORP. KTTA KTTAW

0001213900-26-057837

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 33.41M sh
Shares Diluted Q1 2026 · Mar 31, 2026 24.34M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.21M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.79M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.06M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $50.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $55.16M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $5.34M
Stockholders Equity Q1 2026 · Mar 31, 2026 $54.81M
Stockholders Equity Q1 2026 · Dec 31, 2025 $55.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $12.98M
Stockholders Equity Q1 2026 · Dec 31, 2024 $14.78M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.54M
Total Liabilities Q1 2026 · Dec 31, 2025 $5.02M
Current Assets Q1 2026 · Mar 31, 2026 $52.73M
Current Assets Q1 2026 · Dec 31, 2025 $56.46M
Total Assets Q1 2026 · Mar 31, 2026 $56.35M
Total Assets Q1 2026 · Dec 31, 2025 $60.24M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.12
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.61
Eps Basic Q1 2026 · Mar 31, 2026 −$0.12
Eps Basic Q1 2026 · Mar 31, 2025 −$1.61
Rd Expense Q1 2026 · Mar 31, 2026 $2.94M
Rd Expense Q1 2026 · Mar 31, 2025 $1.73M
Net Income Q1 2026 · Mar 31, 2026 −$2.87M
Net Income Q1 2026 · Mar 31, 2025 −$3.56M
Operating Income Q1 2026 · Mar 31, 2026 −$4.88M
Operating Income Q1 2026 · Mar 31, 2025 −$3.68M